Bookmark and Share

Merck & Co Reports Q3 Results (MRK)

Merck & Co Inc. (NYSE: MRK), a New Jersey-based global healthcare company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health and consumer care products, which it markets directly and through its joint ventures, today reported results for the third quarter ended September 30, 2012.

MRK’s third-quarter consolidated revenues decreased by 4% to $11,488 million from $12,022 million reported in the same period in the previous year. Income before taxes decreased by 6% to $2,218 million from that of $2,352 million reported in the third quarter of 2011. Net income for the quarter increased by 2% to $1,729 million from $1,692 million reported for the same period in the previous year.

The 4% decrease in revenues reflected a 5% decrease in MRK’s major business segment- Pharmaceutical. Revenue in the Animal Health Segment fell 1%.

MRK saw an increase of 15% and 16% in sales of the two diabetes drugs, Januvia and Janumet, respectively. Their combined sales were over $1,380 million for the quarter.

Sales of Singulair medicines decreased 55% to $602 million from $1,336 million. This was mainly due to the expiry of the drug’s patent in the US.  It also noticed decline in sales on Vytorian by 10%, Clarinex by 50%, Remicade by 29%, Primaxin by 24% and on most of its Endocrine and Women’s health medicines and its diversified brand medicines.

Even though MRK’s revenue for the third quarter fell, the company cut its cost proportionately to reduce higher impact on operating income. Income before taxes fell mainly due to fall in revenues and an increase in other expenses.

The decrease in operating income was offset by decrease in income tax rate from 26.7% to 20.5%. Thus, net income increased by 2%.

MRK is working rigorously on many projects to research and develop medicines which will prevent many diseases including human cytomegalovirus infection, osteoporosis in post-menopausal women, type 2 diabetes, Insomnia, etc.

MRK shares have been quite volatile today. The stock has been trading in the range of $45.79 and $46.7650. At last check, the stock was trading 0.47% lower at $46.0815, with volume down from its daily average of 10.74 million to 5.59 million.

Leave a Reply




You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

All stories in are for informational purposes only. This is NOT a stock recommendation. This story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at . About is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.